bioxy tech glutathione peroxidase - Proteases Glutathione Peroxidase Mimetics - KUZMA
Description
Acta Neuropathol, 119:567-577
550 Studies of modulated dosing regimen for nivolumab plus ipilimumab trying to decrease the toxicity display a lower incidence of treatment-related adverse events without weakening the antitumor activity for the treatment of higher/standard-dose nivolumab and a lower-dose ipilimumab
Hypoallergenic and non-comedogenic according to the manufacturer's information
PMC 3229821
The risk-benefit calculation doesn't support chronic use with current evidence
